Galecto, Inc.

NasdaqCM GLTO

Galecto, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -25.16 M

Galecto, Inc. Free Cash Flow is USD -25.16 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 31.86% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Galecto, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -36.93 M, a 25.39% change year over year.
Galecto, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -49.49 M, a -0.54% change year over year.
Galecto, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -49.22 M.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqCM: GLTO

Galecto, Inc.

CEO	Dr. Hans T. Schambye M.D., Ph.D.
IPO Date	Oct. 29, 2020
Location	United States
Headquarters	75 State Street
Employees	13
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

Key trends

Past 5 years